| 摘要 |
A modified diphtheria toxin or fragment thereof comprises at least one modification in at least one T cell epitope, wherein the modified toxin or fragment has a reduced immunogenicity compared to an unmodified diphtheria toxin. In addition, the toxins may be modified to provide reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome (VLS). The modified toxin may be fused to a cell-binding ligand such as an antibody or fragment thereof, or a cytokine, and in particular IL-2. Modified diphtheria toxin/IL-2 fusion proteins are provided. The modified toxins and fusion proteins may be used for the treatment of leukaemias, lymphomas, graft versus host disease or psoriasis. |
